Tools and criteria to select patients with advanced Parkinson’s disease for device-aided therapies: a narrative review

Moes, Harmen R.; Henriksen, Tove; Sławek, Jarosław; Phokaewvarangkul, Onanong; Buskens, Erik; Laar, Teus van

doi:10.1007/s00702-023-02656-z

Cited by 9 publications

(3 citation statements)

References 84 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the second half of 2015, an expert statement was published stating that if a patient with advanced Parkinson’s disease develops 2 h of off-state and/or 1 h of severe dyskinesia per day despite five times daily doses of combined LD therapy (“optimized medication”), DAT options should be considered [ 30 ]. This “5-2-1 rule” has been further refined in subsequent publications [ 49 , 50 , 51 , 52 ].…”

Section: Discussionmentioning

confidence: 99%

Levodopa–Entacapone–Carbidopa Intestinal Gel in the Treatment of Advanced Parkinson’s Disease: A Single Center Real-World Experience

Szatmári,

Szász,

Orbán-Kis

et al. 2024

Pharmaceutics

View full text Add to dashboard Cite

Levodopa–entacapone–carbidopa intestinal gel infusion is a relatively new treatment option for advanced Parkinson’s disease. We aimed to describe and analyze the characteristics of de novo levodopa–entacapone–carbidopa intestinal gel therapy in 20 consecutive patients with advanced Parkinson’s disease. We assessed the profile of motor complications by evaluating the following: motor fluctuations, dyskinesias, and the freezing phenomenon at baseline (before the testing period) and before discharge. The treatment significantly reduced the duration of daily hours spent in off time compared with baseline pre-treatment values from a mean of 4.8 ± 0.9 h/day to a mean of 1.4 ± 0.5 h per day (p < 0.001). The duration and severity of peak-dose dyskinesia were also significantly reduced compared with baseline values. Out of the 10 patients who reported freezing, 8 did not present this complication at the pre-discharge assessment. Significant improvements were observed in Hoehn and Yahr scale scores in both the on and off states. The levodopa–entacapone–carbidopa intestinal gel therapy was well tolerated during the follow-up period immediately after initiation. Despite a relatively severe stage of the disease, all patients experienced a significant improvement in motor fluctuations, dyskinesias, and the freezing phenomenon.

show abstract

Section: Discussionmentioning

confidence: 99%

Levodopa–Entacapone–Carbidopa Intestinal Gel in the Treatment of Advanced Parkinson’s Disease: A Single Center Real-World Experience

Szatmári,

Szász,

Orbán-Kis

et al. 2024

Pharmaceutics

View full text Add to dashboard Cite

show abstract

“…Other approaches, in addition to MANAGE-PD, have also been developed to screen/identify inadequately controlled PD patients [18]. The CDEPA questionnaire (Cuestionario De Enfermedad de Parkinson Avanzada (Questionnaire for Advanced PD)), developed in Spain using Delphi methodology, identifies advanced PD primarily based on "definitive symptoms" whose presence, even when isolated, classifies the PD patient as advanced [4,6].…”

Section: Discussionmentioning

confidence: 99%

Utilization of MANAGE-PD Tool in a Real-World Setting in Germany: A Cross-Sectional Study

Südmeyer,

Pedrosa,

Siebecker

et al. 2024

Brain Sciences

View full text Add to dashboard Cite

MANAGE-PD is a validated, web-based tool to assist physicians in identifying patients with Parkinson’s disease (PD) whose symptoms are inadequately controlled by oral medication. Also, a modified patient version of MANAGE-PD (Parkinson Check) is available in Germany. However, prospective research into the clinical utility of MANAGE-PD is lacking. This non-interventional study aimed to assess the real-world clinical utility of the MANAGE-PD and Parkinson Check in PD patients attending a single visit at specialist clinics and neurologist practices in Germany in 2022. Participants’ disease control was rated by the physicians using their own judgment, and by completing the MANAGE-PD, and by the patients completing the Parkinson Check. Concordance was calculated between the unassisted physician’s assessment and the outcome of MANAGE-PD, as well as the Parkinson Check. A total of 278 patients from 19 sites were included in the analyses, of whom 160 patients (57.6%) were assigned to the same category of disease control by physicians’ judgment and the MANAGE-PD. Concordance was higher in patients treated in specialist clinics (63.9%) than in neurologist practices (43.7%). Concordance between physicians’ and patients’ responses was high (>80%) for each question in the Parkinson Check. MANAGE-PD proved to be especially valuable for general neurologists in identifying patients who should be referred to specialist clinics. The Parkinson Check self-assessment generated promising outcomes that merit its more widespread use.

show abstract

“…Implementation of a user‐friendly and validated screening tool is key to achieving timely referral for DAT without over‐referral. 5 …”

mentioning

confidence: 99%

Patient Referral for Device‐Aided Therapies in Parkinson's Disease is Suboptimal; A Dutch Survey

Moes,

ten Kate,

Buskens

et al. 2023

Movement Disord Clin Pract

Self Cite

View full text Add to dashboard Cite

Tools and criteria to select patients with advanced Parkinson’s disease for device-aided therapies: a narrative review

Cited by 9 publications

References 84 publications

Levodopa–Entacapone–Carbidopa Intestinal Gel in the Treatment of Advanced Parkinson’s Disease: A Single Center Real-World Experience

Levodopa–Entacapone–Carbidopa Intestinal Gel in the Treatment of Advanced Parkinson’s Disease: A Single Center Real-World Experience

Utilization of MANAGE-PD Tool in a Real-World Setting in Germany: A Cross-Sectional Study

Patient Referral for Device‐Aided Therapies in Parkinson's Disease is Suboptimal; A Dutch Survey

Contact Info

Product

Resources

About